127 related articles for article (PubMed ID: 8693644)
1. Agonist and antagonist activities of hydroxyflutamide and Casodex relate to androgen receptor stabilization.
Kemppainen JA; Wilson EM
Urology; 1996 Jul; 48(1):157-63. PubMed ID: 8693644
[No Abstract] [Full Text] [Related]
2. The development of Casodex (bicalutamide): preclinical studies.
Furr BJ
Eur Urol; 1996; 29 Suppl 2():83-95. PubMed ID: 8717469
[TBL] [Abstract][Full Text] [Related]
3. Co-activator and co-repressor interplay on the human androgen receptor.
Papaioannou M; Reeb C; Asim M; Dotzlaw H; Baniahmad A
Andrologia; 2005 Dec; 37(6):211-2. PubMed ID: 16336251
[No Abstract] [Full Text] [Related]
4. Comparison of in vitro effects of the pure antiandrogens OH-flutamide, Casodex, and nilutamide on androgen-sensitive parameters.
Simard J; Singh SM; Labrie F
Urology; 1997 Apr; 49(4):580-6; discussion 586-9. PubMed ID: 9111629
[TBL] [Abstract][Full Text] [Related]
5. Effects of antiandrogens on transformation and transcription activation of wild-type and mutated (LNCaP) androgen receptors.
Berrevoets CA; Veldscholte J; Mulder E
J Steroid Biochem Mol Biol; 1993 Dec; 46(6):731-6. PubMed ID: 8274406
[TBL] [Abstract][Full Text] [Related]
6. Pure antiandrogens disrupt the recruitment of coactivator GRIP1 to colocalize with androgen receptor in nuclei.
Karvonen U; Jänne OA; Palvimo JJ
FEBS Lett; 2002 Jul; 523(1-3):43-7. PubMed ID: 12123801
[TBL] [Abstract][Full Text] [Related]
7. The amino terminus of the human AR is target for corepressor action and antihormone agonism.
Dotzlaw H; Moehren U; Mink S; Cato AC; Iñiguez Lluhí JA; Baniahmad A
Mol Endocrinol; 2002 Apr; 16(4):661-73. PubMed ID: 11923464
[TBL] [Abstract][Full Text] [Related]
8. Antiandrogens prevent stable DNA-binding of the androgen receptor.
Farla P; Hersmus R; Trapman J; Houtsmuller AB
J Cell Sci; 2005 Sep; 118(Pt 18):4187-98. PubMed ID: 16141232
[TBL] [Abstract][Full Text] [Related]
9. Casodex: preclinical studies and controversies.
Furr BJ
Ann N Y Acad Sci; 1995 Jun; 761():79-96. PubMed ID: 7625752
[No Abstract] [Full Text] [Related]
10. Relative potency of bicalutamide (Casodex) and flutamide (Eulexin).
Kolvenbag GJ; Furr BJ
Urology; 1999 Jul; 54(1):194-7. PubMed ID: 10414753
[No Abstract] [Full Text] [Related]
11. The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay.
Ozers MS; Marks BD; Gowda K; Kupcho KR; Ervin KM; De Rosier T; Qadir N; Eliason HC; Riddle SM; Shekhani MS
Biochemistry; 2007 Jan; 46(3):683-95. PubMed ID: 17223690
[TBL] [Abstract][Full Text] [Related]
12. Ultrastructural and quantitative immunohistochemical changes induced by nonsteroid antiandrogens on pituitary gonadotroph population of prepubertal male rats.
Cónsole GM; Jurado SB; Rulli SB; Calandra RS; Gómez Dumm CL
Cells Tissues Organs; 2001; 169(1):64-72. PubMed ID: 11340263
[TBL] [Abstract][Full Text] [Related]
13. Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells.
Godoy-Tundidor S; Hobisch A; Pfeil K; Bartsch G; Culig Z
Clin Cancer Res; 2002 Jul; 8(7):2356-61. PubMed ID: 12114440
[TBL] [Abstract][Full Text] [Related]
14. ICI 176,334: a novel non-steroidal, peripherally-selective antiandrogen.
Furr BJ
Prog Clin Biol Res; 1988; 260():13-26. PubMed ID: 2966405
[No Abstract] [Full Text] [Related]
15. Antiproliferative activity of casodex (ICI 176.334) in hormone-dependent tumours.
Maucher A; von Angerer E
J Cancer Res Clin Oncol; 1993; 119(11):669-74. PubMed ID: 8349724
[TBL] [Abstract][Full Text] [Related]
16. A 90 kDa fragment of filamin A promotes Casodex-induced growth inhibition in Casodex-resistant androgen receptor positive C4-2 prostate cancer cells.
Wang Y; Kreisberg JI; Bedolla RG; Mikhailova M; deVere White RW; Ghosh PM
Oncogene; 2007 Sep; 26(41):6061-70. PubMed ID: 17420725
[TBL] [Abstract][Full Text] [Related]
17. Synergistic activation of androgen receptor by androgen and luteinizing hormone-releasing hormone in prostatic carcinoma cells.
Culig Z; Hobisch A; Hittmair A; Cronauer MV; Radmayr C; Zhang J; Bartsch G; Klocker H
Prostate; 1997 Jul; 32(2):106-14. PubMed ID: 9215398
[TBL] [Abstract][Full Text] [Related]
18. Stabilization of androgen receptor protein is induced by agonist, not by antagonists.
Furutani T; Watanabe T; Tanimoto K; Hashimoto T; Koutoku H; Kudoh M; Shimizu Y; Kato S; Shikama H
Biochem Biophys Res Commun; 2002 Jun; 294(4):779-84. PubMed ID: 12061774
[TBL] [Abstract][Full Text] [Related]
19. A possible explanation for the peripheral selectivity of a novel non-steroidal pure antiandrogen, Casodex (ICI 176,334).
Freeman SN; Mainwaring WI; Furr BJ
Br J Cancer; 1989 Nov; 60(5):664-8. PubMed ID: 2803943
[TBL] [Abstract][Full Text] [Related]
20. Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity.
Wang LG; Liu XM; Kreis W; Budman DR
Biochem Biophys Res Commun; 1999 May; 259(1):21-8. PubMed ID: 10334909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]